⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 2, 2004Science

Nail-Biting Time for Trials of COX-2 Drugs

Jennifer Couzin

View at Publisher

Ask AI

Bookmark

Share

Abstract

CLINICAL TRIALSPreliminary studies suggest that the COX-2 inhibitor Celebrex may stem cancer and Alzheimer's disease, but testing these possibilities has just gotten tougher.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jennifer Couzin (2004) studied this question.

synapsesocial.com/papers/6a8726935ee22a1e35cbaf5c https://doi.org/10.1126/science.306.5702.1673

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1A pair of chitosan receptors confer broad-spectrum fungal resistanceScience · Thu,
2Airflows redefine the cost of aerial transport in the wildScience · Thu,
3Structural basis for size-selective perception of chitin in plantsScience · Thu,
4Modular van der Waals MOSFETs through layer-by-layer chalcogen substitutionsScience · Thu,
5Magic state cultivation on a superconducting quantum processorScience · Thu,

More from Science

Electrically driven chiral emission from plasmonic tunnel junctionsThu,
Engineering ordered two-dimensional defect phases to strengthen structural alloysThu,
Dendritic computation for abstract rule-based flexible decision-makingThu,
Deterministic generation and distribution of genuine multipartite entanglement in macroscopic acoustic resonatorsThu,
Regulation of target gene expression by chromatin-associated protein-coding transcripts in plantsThu,